Denali deal and F-star’s innovative asset centric business model

November 24, 2016 Christoph Graener


Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star’s asset-centric business strategy, the company’s recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.



Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jane Dancer – Chief Business Officer, F-star


Previous Article
Digital health brings game-changing innovation
Digital health brings game-changing innovation

As will be evident at the Digital Medicine Showcase in San Francisco, digital health may become the biggest...

Next Article
Value and the pricing of innovation

Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues...